Alveus Therapeutics emerged with $160 million in financing to advance a Phase 2‑ready lead program that targets the same dual pathway as Amgen’s MariTide, alongside additional candidates including an amylin-directed therapy. The funds will support clinical development and growth of the company’s metabolic pipeline. Investors view the financing as part of continued heavy investor interest in obesity therapeutics and as a sign that venture capital continues to back high‑profile weight‑loss programs despite elevated valuations in the space.